Search Browse Earnings

Cingulate Inc. — SlamSEC

Cingulate Inc.

Nasdaq:CINGNasdaq:CINGW

Pharmaceutical Preparations·KANSAS CITY, KS

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CEO

Schaffer Shane J.

CFO

Callahan Jennifer L.

Revenue

—

Adj. EBITDA

-$22.2M

FY 2024

Net Income

-$23.5M

FY 2024

EPS (Diluted)

-$311.99

FY 2024

Stock Price

$6.84

+6.4%

2026-03-09

52W Range

$3.20 – $7.92

P/E Ratio

-0.0x

Market Cap

$46.2M

Cash

$52,416

FY 2024

Total Debt

$5.4M

FY 2024

Net Debt

$5.4M

FY 2024

Enterprise Value

$51.6M

Debt / EBITDA

-0.2x

FY 2024

EV / EBITDA

-2.3x

Employees

—